|
Shandong Binzhou Zhiyuan Biotechnology Co., Ltd
|
The research on the biological stability of drugs is mainly limited to the anti-enzymatic hydrolysis ability of biological agents such as proteins, peptides and enzymes. For example, l-asparaginase is one of the earliest protein macromolecular biochemical drugs, which is mainly used in acute lymphoblastic leukemia.However, as a kind of enzyme protein preparation, the stability of the drug affects and limits its clinical application to a certain extent.The thermal stability and antitrypsin hydrolysis ability of l-asparaginase -cd inclusion compound were studied after lyophilization. The results showed that -cd can significantly increase the stability of drug and is a good enzyme protectant.Cyclodextrin protein drugs protection reasons might be: protein molecular surface distribution of polar amino acid residues, the polarity of these residues side chain with beta CD molecules form hydrogen bond of hydroxy, thus embedded in the beta CD's mouth water, or residue side chain insert beta CD internal tubular structure, side chain alkyl chain in the hydrophobic bonding and beta CD molecular interactions, the hydrophobic portion of space hole side chain at the same time outside the polar groups and beta CD molecules at the mouth of the close water to form hydrogen bond, forming a stable clathrate.In addition, cyclodextrin can also solve the biological products in water easy to form a dimer, polymer, or easy to be the container wall non-specific adsorption caused by the biological sample activity reduction and other problems. |
Send Inquiry
|
|
Shandong Binzhou Zhiyuan Biotechnology Co., Ltd
|
As the first choice drug for anti-anaerobic bacteria, metronidazole can effectively inhibit and kill periodontal pathogenic anaerobic bacteria such as melanin, gingival bacillus and intermediate bacilli. Its main therapeutic mechanism is the reduction of anaerobic bacteria after nitration, the production of cytotoxic substances, the inhibition of DNA synthesis of sensitive bacteria, and ultimately the death of bacteria. Artificial bezoar metronidazole oral patch can solve the problem of large dosage of raw materials for oral administration of capsules, which is easy to cause severe liver first-pass effect, and metronidazole stimulates gastric mucosa and causes stomach pain and other side effects, and slow onset. . A sustained-release double-layer or single-layer oral patch made of the main drug metronidazole and artificial bezoar, and hydroxypropyl-beta-cyclodextrin plays an indispensable role as a binder. 
|
Send Inquiry
|
|
Shandong Binzhou Zhiyuan Biotechnology Co., Ltd
|
Hydroxypropyl-Beta-Cyclodextrin Cosmetic grade /USP Standard
Name: Hydroxypropyl-Beta-Cyclodextrin Cosmetic grade
Item No.: BZZY-004
CAS NO. : 128446-35-5
Standard: USP Standard
Basic information
Product Name : Hydroxypropyl-Beta-Cyclodextrin
...........................................................................................................................................................
Synonyms : Hydroxypropyl-β-Cyclodextrin
...........................................................................................................................................................
MF : C42H70-nO35(C3H8O2)n
...........................................................................................................................................................
MW : 1134.98+58n
|
Product Specification of Hydroxypropyl-Beta-Cyclodextrin
|
|
Test Standard
|
USP42-NF37
|
|
ITEMS
|
SPECIFICATION
|
|
Molar Substitution
|
0.40-1.50
|
|
Clarity of solution
|
50%(w/v) water solution is clear
|
|
Identification(IR)
|
same absorption bands as USP Hydroxypropyl Betadex RS
|
|
Loss on Drying
|
≤10.0％
|
|
Conductivity
|
10%(w/v) water solution ≤200µS/cm
|
|
Propylene oxide
|
≤1ppm
|
|
Propylene glycol
|
≤2.5％
|
|
Sum of Other Impurities
|
≤1％
|
|
Betadex
|
≤1.5%
|
|
Any other single impurity
|
≤0.25％
|
|
Heavy Metal
|
≤20μg/g
|
|
TAMC(cfu/g)
|
≤1000cfu/g
|
|
TYMC(cfu/g)
|
≤100cfu/g
|
|
Bacterial endotoxins (EU/g)
|
---
|
|
Send Inquiry
|
Pharma Sources Insight June 2024: Globalization on the Go
